... and illustrate its potent influences on the pancreatic TME. In this commentary, we introduce epigenetics in pancreatic cancer and put the findings by Li et al. in context with current knowledge. Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related deaths...

... regulator of tumor progression and metastasis. FOXM1 expression often correlates with poor prognosis and chemotherapy resistance. In the present study, we investigated the association of FOXM1 expression and chemoresistance in pancreatic cancer. Elevated FOXM1 protein levels were associated with gemcitabine...

... 2016 Pancreatic cancer is an aggressive disease, which is resistant to conventional chemotherapy; as a result, innovative therapies are needed. In the present study, we demonstrated a pathogenic role for IL-22 and suggest that blocking IL-22 signalling could be a promising novel treatment...

...-losing patients with pancreatic cancer by an intravenous flooding dose technique. Tracer incorporation into proteins was measured by GC/MS. Patients were restudied after 3 weeks of oral supplement enriched with fish oil (providing 2510 kJ/day and 2 g of eicosapentaenoic acid/day). At baseline, all...

... (0.8–1.18), again no longer significantly different from baseline healthy control values. While weight-losing patients with advanced pancreatic cancer have an increased resting energy expenditure and increased fat oxidation, the energy cost of feeding is, in fact, reduced. Provision of a fish-oil...

...Matthew D. BARBER; Kenneth C. H. FEARON; James A. ROSS The level of the acute-phase response is a major predictor of survival in patients with advanced pancreatic cancer. This study examines the association between the acute-phase protein response, as determined by serum C-reactive protein...